GLO1 and diabetic retinopathy: In this regard, it has also been reported that the angiotensin type 1 receptor blocker, candesartan, prevents angiotensin II‐induced downregulation of GLO1 and that this may contribute to its ability to protect against diabetic retinopathy (Miller et al. 2010).